| 前收市價 | 3.1500 |
| 開市 | 2.7000 |
| 買盤 | 2.4000 |
| 賣出價 | 2.8800 |
| 拍板 | 105.00 |
| 到期日 | 2025-06-20 |
| 今日波幅 | 2.7000 - 2.7000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 557 |
Investing.com HK美股開市前：三大股指期貨跳水 道指期貨大跌400點 GDP現不祥之兆
Investing.com - 周四(25日)開市前，美國股指期貨大跌，道指、納指、標普500、小盤股指數期貨皆跌逾1%，此前美國公佈的第一季度GDP數據釋放利空。一方面，美國第一季度GDP增速從3.9%超預期將至1.6%，預期是2.5%。另一方面，通脹指標之一的美國第一季度GDP平減指數從1.7%升至3.1%，高於預期的3.0%。
- Reuters
UPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.
ReutersMerck raises 2024 profit forecast on strong sales of cancer drug Keytruda
(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell. Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade. The drug is seeing growth from use for additional types of cancers as well as higher patient demand, Chief Financial Officer Caroline Litchfield said.
